167 related articles for article (PubMed ID: 34462784)
1. Validation of ZMYND8 as a new treatment target in hepatocellular carcinoma.
Choi S; Lee KW; Koh HH; Park S; Yeo SY; Joh JW; Choi MS; Kim SH; Park CK; Ha SY
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3517-3534. PubMed ID: 34462784
[TBL] [Abstract][Full Text] [Related]
2. ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis.
Dou C; Mo H; Chen T; Liu J; Zeng Y; Li S; Guo C; Zhang C
Pathol Res Pract; 2021 Mar; 219():153345. PubMed ID: 33517164
[TBL] [Abstract][Full Text] [Related]
3. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma.
Zhao JJ; Pan K; Li JJ; Chen YB; Chen JG; Lv L; Wang DD; Pan QZ; Chen MS; Xia JC
PLoS One; 2011; 6(10):e26608. PubMed ID: 22028922
[TBL] [Abstract][Full Text] [Related]
4. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
5. High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma.
Zhang Y; Tan YF; Jiang C; Zhang K; Zha TZ; Zhang M
Pathol Oncol Res; 2013 Jan; 19(1):79-88. PubMed ID: 22965687
[TBL] [Abstract][Full Text] [Related]
6. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma.
Chen CL; Wang Y; Pan QZ; Tang Y; Wang QJ; Pan K; Huang LX; He J; Zhao JJ; Jiang SS; Zhang XF; Zhang HX; Zhou ZQ; Weng de S; Xia JC
Oncotarget; 2016 Mar; 7(13):16248-61. PubMed ID: 26919247
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-424-5p acts as a potential biomarker and inhibits proliferation and invasion in hepatocellular carcinoma by targeting TRIM29.
Du H; Xu Q; Xiao S; Wu Z; Gong J; Liu C; Ren G; Wu H
Life Sci; 2019 May; 224():1-11. PubMed ID: 30876939
[TBL] [Abstract][Full Text] [Related]
8. Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
Kan H; Huang Y; Li X; Liu D; Chen J; Shu M
Oncotarget; 2016 Mar; 7(12):14336-49. PubMed ID: 26893361
[TBL] [Abstract][Full Text] [Related]
9. New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Fu PY; Hu B; Ma XL; Yang ZF; Yu MC; Sun HX; Huang A; Zhang X; Wang J; Hu ZQ; Zhou CH; Tang WG; Ning R; Xu Y; Zhou J
J Cell Biochem; 2019 Apr; 120(4):6035-6045. PubMed ID: 30368883
[TBL] [Abstract][Full Text] [Related]
10. EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.
Gu F; Yuan S; Liu L; Zhu P; Yang Y; Pan Z; Zhou W
J Cell Mol Med; 2019 Jun; 23(6):4208-4216. PubMed ID: 30957411
[TBL] [Abstract][Full Text] [Related]
11. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
12. TRIP6 promotes tumorigenic capability through regulating FOXC1 in hepatocellular carcinoma.
Wang F; Zhang B; Xu X; Zhu L; Zhu X
Pathol Res Pract; 2020 Apr; 216(4):152850. PubMed ID: 32046874
[TBL] [Abstract][Full Text] [Related]
13. HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.
Zhou ZQ; Zhao JJ; Chen CL; Liu Y; Zeng JX; Wu ZR; Tang Y; Zhu Q; Weng DS; Xia JC
Mol Carcinog; 2019 Jan; 58(1):76-87. PubMed ID: 30182378
[TBL] [Abstract][Full Text] [Related]
14. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
15. The Overexpression of CCAR1 in Hepatocellular Carcinoma Associates with Poor Prognosis.
Ha SY; Kim JH; Yang JW; Kim J; Kim B; Park CK
Cancer Res Treat; 2016 Jul; 48(3):1065-73. PubMed ID: 26511806
[TBL] [Abstract][Full Text] [Related]
16. Validation of ORAOV1 as a new treatment target in hepatocellular carcinoma.
Ha SY; Yeo SY; Lee KW; Kim SH
J Cancer Res Clin Oncol; 2021 Feb; 147(2):423-433. PubMed ID: 33161447
[TBL] [Abstract][Full Text] [Related]
17. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
19. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
20. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma.
Lyu Z; Ma M; Xu Y; Wang X; Zhu Y; Ren W; Li T
Int J Clin Oncol; 2020 Jul; 25(7):1334-1345. PubMed ID: 32347431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
